ArticleBrain tumor research and treatment2024
Clinical Experiences Using CyberKnife for Large-Volume Meningiomas: A Preliminary Study.
Article in Brain tumor research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis.Journal of neuro-oncology · 2025Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis preliminary study evaluates the safety and efficacy of CyberKnife radiosurgery (CKRS) for large-volume meningiomas (≥10 cm³), where surgical options may be limited due to tumor location or patient health conditions.
methodsWe retrospectively analyzed 18 patients with meningiomas treated with CKRS at Gyeongsang National University Hospital between 2010 and 2020. Tumor control and survival rates were evaluated, with follow-up imaging performed regularly.
resultsCKRS achieved a 5-year overall survival rate of 92.3% and a 5-year tumor control rate of 93.8%. Symptomatic peritumoral edema occurred in 61.1% of patients, with 16.7% requiring surgical intervention.
conclusionCKRS appears to be a promising option for patients with large meningiomas, showing good tumor control and manageable complications. Further studies with larger cohorts are necessary to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.